The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease.

Abstract

No therapeutics are approved for the treatment of filovirus infections. Bepridil, a calcium channel blocker developed for treating angina, was identified as a potent inhibitor of filoviruses in vitro, including Ebola and Marburg viruses, and Ebola virus in vivo. We evaluated the efficacy of bepridil in a lethal mouse model of Marburg virus disease. A dose of 12 mg/kg bepridil once or twice daily resulted in 80% or 90% survival, respectively. These data confirm bepridil's broad-spectrum anti-filovirus activity warranting further investigation of bepridil, or improved compounds with a similar mechanism, as a pan-filovirus therapeutic agent.

• Authors: Lisa Evans DeWald, Julie Dyall, Jennifer M Sword, Lisa Torzewski, Huanying Zhou, Elena Postnikova, Erin Kollins, Isis Alexander, Robin Gross, Yu Cong, Dawn M Gerhardt, Reed F Johnson, Gene G Olinger Jr, Michael R Holbrook, Lisa E Hensley, Peter B Jahrling
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 218 Issue suppl_5 Pg. S588-S591 (11 22 2018) ISSN: 1537-6613 [Electronic] United States
• PMID: 29982632 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)

Chemical References

• Calcium Channel Blockers
• Bepridil

Topics

• Animals
• Bepridil (therapeutic use)
• Calcium Channel Blockers (therapeutic use)
• Chlorocebus aethiops
• Disease Models, Animal
• Female
• Marburg Virus Disease (drug therapy, mortality)
• Mice
• Mice, Inbred BALB C
• Vero Cells